Alliance of Community Health Plans

In an interview at AMCP Nexus 2026, Carmen Witsken, PharmD, of ACHP, outlined a proposed national risk pool for the costliest cell and gene therapies.

At AMCP Nexus 2026, Carmen Witsken, PharmD, discusses high upfront cell and gene therapy costs and the case for a national risk pool.

Early modeling put sickle cell gene therapy coverage near $0.11 per member per month.

Brian Corvino, MBA, managing director, Life Sciences and Health Care Practice, Deloitte Consulting, LLP, offered an overview of how the surge of innovation in oncology—and resulting drug approvals—dominate the biopharmaceutical sector. He spoke at the Community Oncology Alliance's Payer Exchange Summit.

Praveen Thadani, president of Priority Health, has been recognized for his tireless work at reducing health care disparities over a 25-year career with the 2022 Bernard J. Tyson Health Equity Award.